Design
A randomized, placebo-controlled, double-blind, counterbalanced crossover design was utilized. Participants were assessed immediately prior to and following 2 4-wk crossover treatment periods. The study was approved by the University Ethical Approval System at Northumbria University and was conducted according to the Declaration of Helsinki (2013). The study was registered at 